Webcasts from the ECCO'19 Scientific Programme

"Research drives clinical care"

Webcasts from the Scientific Programme of the 14th Congress of ECCO will be uploaded as they become available.


The scientific programme is structured around basic science, translational medicine and clinical sessions, given by some of the world’s top specialists. It includes oral presentations of the best abstracts, the announcement of ECCO Fellowships and Grants and summary presentations of new ECCO Guidelines. The focus of all sessions is clinical practice founded on science, with practical messages to take home. Scientific sessions are held from Thursday to Saturday, March 7-9, 2019. The congress registration fee includes access to all scientific sessions.

Select a Scientific Session below to view a list of available content.

Scientific session 1: Silencing IBD

Can we prevent IBD?

Jean-Frédéric Colombel, New York, United States

► Watch now


OP01: In-depth characterisation of host-genetics and gut microbiome unravels novel host-microbiome interactions in Inflammatory Bowel Disease

S. Hu, Groningen, Netherlands

► Watch now

VIEW ABSTRACT 


Can we cure IBD?

Arthur Kaser, Cambridge, United Kingdom

► Watch now


OP02: The role of PTPN2 SNP in the pathogenesis of fibrosis in Crohn’s Disease

C. Li, Richmond, United States

► Watch now

VIEW ABSTRACT


OP03: Inhibition of autophagy exacerbates intestinal fibrosis and EMT

J. Cosin-Roger, Valencia, Spain

-no consent reseived-

VIEW ABSTRACT 


Are fibrotic complications reversible?

Geert D'Haens, Amsterdam, The Netherlands

Massimo Pinzani, London, United Kingdom

► WATCH NOW

Scientific session 2: Complementary treatments: The good and the bad

The crazy stuff - what your patients are taking and why?

Fernando Gomollón Garcia, Zaragoza, Spain

► Watch now


OP04: Turning sweet in Inflammatory Bowel Disease: Glycans as novel immunomodulators of T cell-mediated immune response

S. Pinho, Porto, Portugal

-no consent received-

VIEW ABSTRACT


ECCO Topical Review on complementary medicine

Joana Torres, Lisbon, Portugal

Stephan Vavricka, Zurich, Switzerland

► Watch now


OP05: Crohn’s Disease exclusion diet is equally effective but better tolerated than exclusive enteral nutrition for induction of remission in Mild to Moderate Active Paediatric Crohn’s Disease: A prospective randomised controlled trial

A. Levine, Holon, Israel

-no consent received-

VIEW ABSTRACT 


OP06: Gut-brain-axis revisited: Shedding light on the mucosa associated microbial composition in IBD patients with psychological distress, anxiety and depression

L. Biedermann, Zurich, Switzerland

-no consent received-

VIEW ABSTRACT 


Psychological support in IBD

Yoram Inspector, London, United Kingdom

► Watch now

Scientific session 3: Precision medicine: Lessons to learn and paths to the future

What is system biology?

Dermot McGovern, Los Angeles, United States

► Watch now


Multi-omics profiling of IBD

Jonas Halfvarson, Örebrö, Sweden

► Watch now


OP07: Analysing intestinal organoids in a multi-omics, systems biology framework to investigate functional processes affected in Crohn’s Disease due to autophagy impairment

T. Korcsmaros, Norwich, United Kingdom

► Watch now

VIEW ABSTRACT


OP08: Long-term efficacy and pharmacodynamics of the anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) monoclonal antibody SHP647 in Crohn’s Disease: The OPERA II study

G. D'Haens, Amsterdam, Netherlands

-no consent received-

VIEW ABSTRACT


Stratifying by disease biology to choose the right drug for the right patient

Charlie Lees, Edinburgh, United Kingdom

► Watch now

Scientific session 4: Best practice in UC

When do you start a biologic?

Simon Travis, Oxford, United Kingdom

► Watch now


OP09: Histological remission and mucosal healing in a randomised, placebo-controlled, phase 2 study of etrasimod in patients with Moderately to Severely Active Ulcerative Colitis

L. Peyrin-Biroulet, Vandœuvre-lès-Nancy, France

► Watch now

VIEW ABSTRACT


OP10: Systems genomics of Ulcerative Colitis: Combining GWAS and signalling networks for patient stratification and individualised drug targeting in Ulcerative Colitis

J. Brooks, Norwich, United Kingdom

► Watch now

VIEW ABSTRACT


OP11: Organoids derived from inflamed intestinal biopsies of patients with Ulcerative Colitis lose their inflammatory phenotype during ex vivo culture

K. Arnauts, Leuven, Belgium

► Watch now

VIEW ABSTRACT


Where is the exit?

Marc Ferrante, Leuven, Belgium

► Watch now


OP12: Targeting inflammation in Ulcerative Colitis by inhibiting glucose uptake

R. Gropp, Munich, Germany

► Watch now

VIEW ABSTRACT


OP13: Molecular response to ustekinumab in Moderate to Severe Ulcerative Colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI phase 3 induction study

K. Li, Spring House, United States

► Watch now

 VIEW ABSTRACT


OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with Moderately to Severely Active Ulcerative Colitis: Data from the U-ACHIEVE study

W. J. Sandborn, La Jolla, United States

► Watch now

 VIEW ABSTRACT


Precision surgery in UC

Yves Panis, Clichy, France

► Watch now

Scientific session 5: IBD around the world

Vaccination and travelling with IBD: An update

Jean-François Rahier, Yvoir, Belgium

► Watch now


OP15: Cost-analysis in a prospective European population-based inception cohort. Is there a cost-saving effect of biological therapy?

Johan Burisch, Frederikssund, Denmark

-no consent received-


Management of IBD outside of Europe: The example of India

Rupa Banerjee, Hyderabad, India

► Watch now 


OP16: A randomised, multicentre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of Mild to Moderate Ulcerative Colitis: Efficacy results

S. Bloom, London, United Kingdom

► Watch now

VIEW ABSTRACT


OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies

M. Suarez-Farinas, New York, United States

► Watch now

VIEW ABSTRACT


East meets West: Epidemiology of IBD

Johan Burisch, Copenhagen, Denmark
Siew Ng, Hong Kong, China

-no consent received-


Scientific session 6: New ways of doing endoscopy and imaging in IBD

Assessing bowel damage in CD from adult to childhood

Anne Griffiths, Toronto, Canada
► Watch now


OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s Disease: The paediatric Crohn's Disease adalimumab level-based optimisation treatment (PAILOT) trial

A. Assa, Petach Tikva, Israel

► Watch now

VIEW ABSTRACT


Best practice in screening for dysplasia

Marietta Iacucci, Birmingham, United Kingdom

► Watch now


OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve Ulcerative Colitis

Y. Haberman, Tel Hashomer, Israel

► Watch now

VIEW ABSTRACT


OP20: Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s Disease

A. Lewis, London, United Kingdom

► Watch now

VIEW ABSTRACT

Scientific session 7: ECCO Fellowships and Grants

Outcomes from ECCO Pioneer Award 2017: Faecal transplantation using a novel conditioning method for donor and recipient in mild to moderate treatment refractory colitis in Inflammatory Bowel Disease

Arie Levine, Tel Aviv, Israel

► Watch now


Outcomes from the ECCO Fellowship 2018: Role of TNF-inducible gene-6 (TSG-6) in fistulising Crohn's Disease

Sudharshan Elangovan, Milan, Italy

► Watch now


Outcomes from the ECCO Fellowship 2018: Monocyte-derived macrophages as crucial players in the resolution of inflammation and tissue repair in Inflammatory Bowel Disease

Sales Ibiza, Lisbon, Portugal

► Watch now


Outcomes from the ECCO-IOIBD Fellowship 2017: Precision medicine for IBD using advanced machine learning

Aria Zand, Los Angeles, United States

► Watch now


Outcomes from the ECCO-IOIBD Fellowship 2018: Deciphering the gut-specific B cell response in Inflammatory Bowel Disease

Mathieu Uzzan, Clichy, France

► Watch now


Announcement of ECCO Fellowships and Grants 2019

► Watch now

Scientific session 8: IBD Horizons

OP21: ABX464 is safe and efficacious in a proof of concept study in Ulcerative Colitis patients

J.-M. Steens, Paris, France

► Watch now

VIEW ABSTRACT


OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental Colitis

M. Barnhoorn, Leiden, Netherlands

-no consent received-

VIEW ABSTRACT


OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates Colitis in various animal models

J. Shin, Yongin, South Korea

► Watch now

VIEW ABSTRACT


OP24: Effectiveness and safety of ustekinumab 90 mg every four weeks in Crohn's Disease

M. Fumery, Amiens, France

► Watch now

VIEW ABSTRACT


OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s Disease

E. Dreesen, Leuven, Belgium

► Watch now

VIEW ABSTRACT


OP26: Long-term safety of vedolizumab in Ulcerative Colitis and Crohn’s Disease: Final results from the GEMINI LTS study

R. Panaccione, Calgary, Canada

► Watch now

VIEW ABSTRACT


Scientific session 9: Basic Science: Immune cells and microbes: A happy marriage?

Metabolic profiling - the new player in microbiome research

Stefan Schreiber, Kiel, Germany

► Watch now


OP27: High-dimensional mass cytometry reveals the immune cell landscape in Inflammatory Bowel Disease

L. Ouboter, Leiden, Netherlands

-no consent received-

VIEW ABSTRACT


OP28: Host-microbial crosstalk in the pathogenesis of inflammation and cancer in primary sclerosing cholangitis

A. Geremia, Oxford, United Kingdom

-no consent received-

VIEW ABSTRACT


Using mucosal immune pathways to predict disease outcome

Ahmed Hegazy, Berlin, Germany

► Watch now


OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer

L. R. Lopetuso, Roma, Italy

► Watch now

VIEW ABSTRACT


OP30: Serum proteomic profiling predicts and diagnoses pouchitis in Ulcerative Colitis patients undergoing ileal pouch-anal anastomosis

K. Machiels, Leuven, Belgium

► Watch now

VIEW ABSTRACT


Resolution pathways: Next frontier to control intestinal inflammation

Silvia D'Alessio, Milan, Italy

-no consent received-

Scientific session 10: The cycle of IBD life in clinical practice

Challenges in managing the elderly

Guillaume Savoye, Rouen, France

► Watch now


OP31: TP53 mutation in human colonic organoids acquires resistance to in vitro long-term inflammation

K. Tsuchiya, Tokyo, Japan

-no consent received-

VIEW ABSTRACT


OP32: A novel mechanism of colonic epithelial-T cell cross-talk is dysregulated in IBD

R. J. Dart, London, United Kingdom

-no consent received-

VIEW ABSTRACT


The reproductive phase: Practical recommendations

Ailsa Hart, London, United Kingdom

► Watch now


Oral Presentation 33: BUB1: A new player in the development of Crohn’s Disease (CD)-associated fibrosis

V. Garlatti, Rozzano, Italy

-no consent received-

VIEW ABSTRACT


Oral Presentation 34: VARSITY: A Double-Blind, Double-Dummy, Randomised, Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis

Stefan Schreiber, Kiel, Germany

► Watch now

VIEW ABSTRACT


OP35: Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s Disease: Long-term data from CALM

Clara Yzet, Amiens, France

► Watch now

VIEW ABSTRACT


Cancer risk in children with IBD, an under-recognized issue

Arie Levine, Tel Aviv, Israel

► Watch now 

Scientific session 11: Towards the future of IBD

Artificial intelligence augmenting medical management

Geert Meyfroidt, Leuven, Belgium

► Watch now


OP36: A colonic gene expression signature predicts non-response to anti-inflammatory therapies in Inflammatory Bowel Disease

T. Sato, Spring House, United States

-no consent received-

VIEW ABSTRACT


Robot and surgeon: How will a partnership work?

Antonino Spinelli, Milan, Italy

► Watch now


OP37: Efficacy and safety of ustekinumab as maintenance therapy in Ulcerative Colitis: Week 44 results from UNIFI

W. J. Sandborn, New York, United States

► Watch now

VIEW ABSTRACT


OP38: Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with Moderately to Severely Active Ulcerative Colitis

G. R. D'Haens, Amsterdam, Netherlands

► Watch now

VIEW ABSTRACT


Big data: Potential for transforming IBD research and care

Ignacio Hernandez-Medrano, Madrid, Spain

-no consent received-

Scientific session 12: ECCO Lecture

ECCO Lecture: Inflammatory cytokines from discoveries to therapies

Charles Dinarello, Denver, United States

► Watch now


Awards and closing remarks

Silvio Danese, Milan, Italy

► Watch now